Novo Nordisk partners with OpenAI

Novo Nordisk said on April 14 that it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and commercial operations. (novonordisk.com) (cnbc.com) The Danish drugmaker said the goal is to bring “new and better treatment options to patients faster” by using OpenAI tools to analyze complex datasets, identify drug targets and speed decision-making. (novonordisk.com) (usnews.com) Novo said the rollout will cover the company globally, and outside reports said it will start with pilots in research and development, manufacturing and commercial teams before broader integration by the end of 2026. (biospace.com) (pharmaceutical-technology.com) Drug discovery is the process of turning a biological hunch into a medicine, and OpenAI said that early-stage research often takes years before a drug ever reaches regulators. Its new life-sciences model, GPT-Rosalind, is built to help with chemistry, protein engineering, genomics and experimental planning. (openai.com) Novo chief executive Mike Doustdar said AI can let researchers analyze data at a scale that was “previously impossible,” identify patterns they could not see before, and test hypotheses faster. OpenAI chief executive Sam Altman said AI can help life-sciences companies “live better, longer lives” through faster research. (cnbc.com) (biospace.com) The agreement is not just about lab work. Novo said it will use OpenAI across the chain from discovery to delivery, and the company also said the partnership includes workforce upskilling, strict data governance and human oversight. (biospace.com) (novonordisk.com) Novo has been building this AI stack for months. Nvidia said in 2025 that it was working with Novo Nordisk and Denmark’s AI center on customized models and agents for early research and clinical development using the Gefion sovereign AI supercomputer. (nvidia.com) (dcai.dk) The timing is sensitive for Novo. Reuters reported in February that the company warned of “unprecedented” price pressure in 2026, and Novo’s investor calendar shows first-quarter results are due on May 6. (marketscreener.com) (novonordisk.com) Investors initially welcomed the OpenAI deal, with CNBC reporting the stock rose 2.8% shortly after the opening bell on April 14. The harder test will come from whether faster research and operations produce drugs that work, win approval and sell. (cnbc.com)